NexImmune Appoints Sol Barer as Chairman of the Board of Directors
December 16 2019 - 7:30AM
NexImmune, a clinical-stage biopharmaceutical company developing
novel immune-therapeutics based on a proprietary Artificial Immune
Modulation (AIM) nanotechnology platform, announced that Sol Barer,
PhD has been appointed as the Company’s Chairman of the Board of
Directors. In January 2017, Barer & Son Capital led a
consortium of private investors to acquire NexImmune, at which time
he served as a Board Observer to the Company.
Dr. Barer commented, "NexImmune has developed a potentially
transformative technology platform with broad application across a
range of disease areas, spanning Oncology, Autoimmune and
Infectious Disease. As our lead T cell therapy candidates for Acute
Myeloid Leukemia and Multiple Myeloma enter Phase 1 clinical
testing, I look forward to leading the Board and working with the
NexImmune leadership team to expand the development of current and
future applications of this unique platform to the benefit of an
even broader population of patients."
“We are extremely pleased to welcome Sol to our Board of
Directors in the role of Chairman. Sol is a titan in the industry
with hands-on experience building, leading and financing companies
based on innovative science and technologies that have potential to
address significant unmet patient needs . We look forward to
his insights and experience to help guide the development of our
technology and to position the company for success as we transition
into a clinical stage company,” stated Scott Carmer, President and
CEO of NexImmune. Dr. Barer is a founder and former Chairman,
President, COO and CEO of Celgene (NASDAQ: CELG). He brings more
than 30 years of experience in the biotechnology industry to the
NexImmune Board of Directors. Dr. Barer currently serves as Board
Chair for Teva Pharmaceuticals (NYSE: TEVA), Centrexion
Therapeutics (NASDAQ: CNTX), and Aevi Genomic Medicine (NASDAQ:
GNMX). He is also lead director for Contrafect Corp. (NASDAQ: CFRX)
and a member of the Board of Directors for 3DBio Therapeutics.
Dr. Barer is also the Founding Chair of the Hackensack
Meridian Health Center for Discovery & Innovation and is a
co-founder of Barer & Son Capital, an investment fund focused
on capitalizing early stage breakthrough biotechnology
companies.The NexImmune Board of Directors currently includes:
- Sol Barer, PhD – Chairman of the Board
- Timothy Bertram, PhD – Chair, Compensation Committee; CEO,
TwinCity Bio
- Scott P. Carmer – President & CEO, NexImmune
- Paul D'Angio, RPH, MSJ – former SVP, Global Technical
Operations, Celgene
- Alan S. Roemer, MBA, MPH – Chair, Audit Committee; Founding
Leadership Team, Roivant Sciences
- Tony Yao, MD, PhD – Chair, Science & Technology Committee;
Portfolio Manager, Arrowmark Partners
- Zhengbin (Bing) Yao, PhD – Chair, Nomination and Governance
Committee; CEO, Viela Bio
About NexImmune NexImmune is a clinical-stage
biopharmaceutical company developing novel immune-therapeutics
based on the proprietary Artificial Immune Modulation (AIM)
nanotechnology platform. The AIM platform enables the ability to
expand multi-antigen specific T cells with enhanced anti-tumor
properties without the need for genetic manipulation. NexImmune is
leveraging the AIM technology platform to develop a pipeline of
products to treat cancer and auto-immune
diseases.NEXI-001, an investigational agent, is
being developed for the treatment of acute myeloid leukemia (AML)
or myelodysplastic syndrome (MDS) patients with relapsed disease
after an allogeneic hematopoietic cellular transplant (allo-HCT).
NEXI-002, an investigational agent, is being
developed for the treatment of relapsed / refractory Multiple
Myeloma for patients who have failed >3 prior lines of
therapy.
Contact
Chad Rubin Solebury Trout crubin@soleburytrout.com
+1-646-378-2947
Celgene (NASDAQ:CELG)
Historical Stock Chart
From Jul 2024 to Aug 2024
Celgene (NASDAQ:CELG)
Historical Stock Chart
From Aug 2023 to Aug 2024